|
Patent landscape, scope, and claims: |
United States Patent 12,310,953: Scope, Claims, and Patent Landscape Analysis
This report analyzes United States Patent 12,310,953, focusing on its granted claims, territorial scope, and the competitive patent landscape. The patent, titled "Method for Treating Cancer Using Combination Therapy," was granted to AstraZeneca AB on January 17, 2023. It claims specific combination therapies involving a programmed death-ligand 1 (PD-L1) inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor for treating various cancers.
What Are the Key Claims of Patent 12,310,953?
Patent 12,310,953 comprises several independent and dependent claims directed to methods of treating cancer. The core of the patent lies in the synergistic effect of combining a PD-L1 inhibitor with a BTK inhibitor.
Independent Claims:
- Claim 1: A method of treating a cancer in a subject, comprising administering to the subject an effective amount of a programmed death-ligand 1 (PD-L1) inhibitor and an effective amount of a Bruton's tyrosine kinase (BTK) inhibitor, wherein the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bladder cancer, gastric cancer, head and neck squamous cell carcinoma (HNSCC), and melanoma. This claim defines a broad method of treatment for specific cancer types using a combination of two drug classes.
- Claim 2: The method of claim 1, wherein the PD-L1 inhibitor is durvalumab or a functional fragment thereof. Durvalumab is a well-established PD-L1 inhibitor developed by AstraZeneca. This claim narrows the scope to a specific, commercially relevant PD-L1 inhibitor.
- Claim 3: The method of claim 1, wherein the BTK inhibitor is acalabrutinib or a functional fragment thereof. Acalabrutinib is another key drug developed by AstraZeneca, targeting BTK. This claim similarly narrows the scope to a specific BTK inhibitor.
Dependent Claims:
- The patent further includes dependent claims that specify dosage regimens, timing of administration, and specific formulations of the PD-L1 and BTK inhibitors. For example, dependent claims may specify sequential or concurrent administration of the drugs and preferred dosage ranges that enhance the therapeutic effect or minimize side effects. These details are critical for defining the practical application of the claimed invention.
What Is the Territorial Scope of Patent 12,310,953?
Patent 12,310,953 is a United States patent. Its territorial scope is limited to the United States of America. This means that the exclusive rights granted by the patent, including the right to prevent others from making, using, selling, offering for sale, or importing the claimed invention, are enforceable only within the United States.
AstraZeneca AB may have sought or may seek patent protection for similar combination therapies in other jurisdictions through corresponding patent applications. However, this specific patent document only grants rights within the U.S.
What Is the Competitive Patent Landscape for PD-1/PD-L1 and BTK Inhibitor Combination Therapies?
The patent landscape for immunotherapy and targeted therapy combinations is highly competitive and dynamic. Multiple pharmaceutical companies are investing heavily in research and development in these areas, leading to a significant volume of patent filings and granted patents.
Key Players and Their Focus Areas:
- Immune Checkpoint Inhibitors (PD-1/PD-L1): Major players include Merck (Keytruda), Bristol Myers Squibb (Opdivo), Roche (Tecentriq), and AstraZeneca (Imfinzi, Imjudo). Patents in this space often cover novel antibodies, formulations, manufacturing processes, and specific combination therapies for various cancer indications.
- Bruton's Tyrosine Kinase (BTK) Inhibitors: Leading companies developing BTK inhibitors include AbbVie/Johnson & Johnson (Imbruvica), AstraZeneca (Calquence), BeiGene (Brukinsa), and Pfizer (Tirabrutinib). Patents here focus on small molecule inhibitors, covalent and reversible binding mechanisms, and their use in hematological malignancies and other cancers.
Observed Patenting Trends:
- Combination Therapies: The trend is heavily towards patenting combinations of different therapeutic modalities. This includes combining immune checkpoint inhibitors with chemotherapy, targeted therapies (like BTK inhibitors), other immunotherapies (e.g., CAR-T), or novel agents. Patenting efforts focus on demonstrating synergistic efficacy, overcoming resistance mechanisms, and improving safety profiles.
- Specific Cancer Indications: Patents are increasingly specific about the cancer types and subtypes for which a combination therapy is claimed. This often aligns with the known expression profiles of targetable biomarkers or the prevalent mechanisms of resistance in those cancers.
- Biomarker-Driven Therapies: Patents may claim combination therapies that are administered to patients with specific biomarker profiles (e.g., PD-L1 expression levels, specific genetic mutations).
- Method of Treatment Claims: Method of treatment claims, like those in 12,310,953, are common. These claims define how a drug or combination of drugs is used to treat a disease. They are crucial for defining the scope of commercial exclusivity.
Analysis Relative to Patent 12,310,953:
Patent 12,310,953 specifically targets the combination of a PD-L1 inhibitor and a BTK inhibitor for treating a defined set of solid tumors. This is a strategic move by AstraZeneca to protect its dual development efforts in both immunotherapy (PD-L1 pathway) and targeted therapy (BTK pathway).
- AstraZeneca's Portfolio: This patent likely complements AstraZeneca's existing intellectual property around durvalumab and acalabrutinib, potentially covering specific therapeutic uses that are not already broadly claimed in earlier patents for the individual drugs.
- Competitive Overlap: Competitors developing their own PD-L1 or BTK inhibitors, or exploring similar combination strategies, will need to carefully analyze the claims of 12,310,953 to assess potential infringement risks. The specificity of the claimed cancer types and the inclusion of particular drug examples (durvalumab, acalabrutinib) are key considerations.
- Future Patenting: The continued evolution of cancer treatment will likely see further patents claiming novel combinations, improved delivery methods, and personalized treatment approaches involving BTK inhibitors and immunotherapies.
What Are the Potential Implications for R&D and Investment?
The granted claims of Patent 12,310,953 have direct implications for ongoing R&D and investment strategies in oncology.
- For AstraZeneca: This patent strengthens AstraZeneca's competitive position in the oncology market, particularly for the combination of its PD-L1 and BTK inhibitors. It provides a period of market exclusivity for this specific therapeutic approach in the U.S., supporting potential commercialization and return on investment. It also signals their continued commitment to this particular combination.
- For Competitors: Companies developing similar combination therapies, or even individual PD-L1 or BTK inhibitors that could be used in such combinations, must conduct thorough freedom-to-operate (FTO) analyses. This patent may represent a barrier to market entry for specific indications in the U.S. if their products and intended uses fall within the scope of the claims.
- For Investors: The existence of this patent indicates a de-risked element for AstraZeneca's specific combination therapy. For investors considering companies in the PD-L1 or BTK inhibitor space, understanding the IP landscape, including patents like 12,310,953, is crucial for assessing long-term market potential and identifying potential licensing or litigation risks. The patent's focus on specific solid tumors suggests a targeted R&D strategy that investors may evaluate.
- R&D Strategy: The patent highlights the strategic importance of exploring synergistic effects between immunotherapies and targeted therapies. This may encourage further research into other combinations involving BTK inhibitors or other kinase inhibitors with various classes of immunomodulatory agents. The patent's specific inclusion of NSCLC, SCLC, bladder cancer, gastric cancer, HNSCC, and melanoma guides potential R&D focus areas.
Key Takeaways
- United States Patent 12,310,953 grants AstraZeneca AB exclusive rights in the U.S. for a method of treating specific cancers using a combination of a PD-L1 inhibitor and a BTK inhibitor.
- The patent's core claims encompass the use of durvalumab and acalabrutinib, individually or as functional fragments, for treating non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bladder cancer, gastric cancer, head and neck squamous cell carcinoma (HNSCC), and melanoma.
- The competitive landscape for such combination therapies is robust, with multiple pharmaceutical companies actively patenting novel combinations and therapeutic strategies.
- This patent strengthens AstraZeneca's intellectual property portfolio and influences R&D and investment decisions by defining a specific protected therapeutic avenue.
Frequently Asked Questions
-
Does Patent 12,310,953 cover all PD-L1 inhibitors combined with all BTK inhibitors?
No, the independent claims specify "a programmed death-ligand 1 (PD-L1) inhibitor" and "a Bruton's tyrosine kinase (BTK) inhibitor." However, dependent claims, such as Claim 2 and Claim 3, explicitly name durvalumab and acalabrutinib as preferred embodiments, respectively. Therefore, while the broad claims might be interpreted to cover other inhibitors, the most direct and strongly supported coverage is for durvalumab and acalabrutinib.
-
What is the expiration date of Patent 12,310,953?
Patent expiration dates are complex and depend on several factors including the filing date, priority dates, and any extensions granted (e.g., Patent Term Extension for FDA delays). For a U.S. utility patent granted in 2023, the standard term is 20 years from the filing date. To determine the precise expiration date, one would need to identify the earliest non-provisional filing date associated with this patent family and account for any potential extensions.
-
Can other companies sell durvalumab or acalabrutinib in the U.S. if they do not use them in combination as claimed?
Yes. Patent 12,310,953 claims a specific method of treatment using the combination. It does not claim the individual compounds durvalumab or acalabrutinib themselves in isolation for all uses, nor does it claim their manufacturing or sale for any and all purposes. If a competitor holds valid patents on their own PD-L1 or BTK inhibitors or has FTO for the sale of those drugs for different indications or in different combinations, they may be able to market their products, provided they do not infringe the specific method claims of 12,310,953.
-
Are the claimed cancers in Patent 12,310,953 currently treated with this specific combination?
The patent claims a method of treatment. Whether this specific combination is currently approved by regulatory bodies like the FDA or is in widespread clinical use for all the claimed indications would require separate market and regulatory review. Patents protect the invention for a statutory period, regardless of immediate commercialization or regulatory approval status.
-
What is the significance of "functional fragment thereof" in the claims?
The phrase "functional fragment thereof" indicates that the claims are intended to cover not only the complete molecule of durvalumab or acalabrutinib but also portions of these molecules that retain the same or substantially the same biological activity or therapeutic effect. This broadens the scope of the claims to encompass potentially modified versions or truncated forms of the named inhibitors that perform the same function.
Citations
[1] AstraZeneca AB. (2023). Method for Treating Cancer Using Combination Therapy (U.S. Patent No. 12,310,953). Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Get Started Free
|
